3.2 Analgesics, Opioids, NSAIDs & Central Nervous System Agents

National Board Dental Hygiene Examination NBDHE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Head, Neck & Dental Anatomy, Histology & Embryology

1.1 Head & Neck Cranial Nerves, Osteology & Musculature 1.2 Tooth Morphology, Occlusion & Root Anatomy 1.3 Tooth Development, Histology & Embryology 1.4 Oral Physiology, Salivary Gland Function & TMJ Dynamics 1.5 General Pathology, Inflammation & Immunity Concepts

2 Chapter 2: Oral Pathology, Microbiology & Biofilm Ecology

2.1 Oral Mucosal Lesions, Soft Tissue & Salivary Pathology 2.2 Hard Tissue Anomalies, Cysts, Neoplasms & Radiographic Pathology 2.3 Periodontal Pathology, Plaque Biofilm Ecology & Microbiology 2.4 Cariology, Demineralization Mechanics & Fluoride Chemistry 2.5 Systemic Disease Manifestations & Oral Cancer Risk Factors 2.6 Genetic Conditions, Immunopathology & Diagnostic Biopsy Protocols

3 Chapter 3: Dental Pharmacology, Biochemistry & Nutrition

3.1 Autonomic Drugs, Cardiovascular & Respiratory Pharmacology 3.2 Analgesics, Opioids, NSAIDs & Central Nervous System Agents 3.3 Antimicrobial Therapy, Antibiotic Prophylaxis & Antivirals/Antifungals 3.4 Nutritional Biochemistry, Vitamins, Minerals & Dietary Analysis 3.5 Endocrine Pharmacology, Diabetic Care & Bone Metabolism Agents 3.6 Special Population Pharmacotherapeutics & Drug Interactions

4 Chapter 4: Patient Assessment, Risk Evaluation & Radiographic Interpretation

4.1 Health History Review, ASA Physical Status & Medical Risk Assessment 4.2 Comprehensive Extraoral/Intraoral Examination & Soft Tissue Inspection 4.3 Periodontal Assessment, Probing Techniques & Furcation Classification 4.4 Hard Tissue Examination, Caries Detection & Restorative Evaluation 4.5 Dental Radiography Principles, Physics, Technique & Radiation Safety 4.6 Radiographic Interpretation, Normal Landmarks & Pathologic Artifacts

5 Chapter 5: Periodontal Therapy, Instrumentation & Preventive Services

5.1 Periodontal Disease Etiology, Pathogenesis & Host Response 5.2 Non-Surgical Periodontal Therapy (NSPT) & Scaling/Root Planing (SRP) 5.3 Dental Hygiene Instrumentation, Ergonomics & Sharpness Maintenance 5.4 Preventive Oral Health Agents, Dentifrices, Rinses & Remineralization 5.5 Surgical Periodontal Therapy Overview & Maintenance Protocols 5.6 Patient Motivation, Behavioral Change & Oral Hygiene Instruction 5.7 Care Planning for Special Needs, Medically Compromised & Geriatric Patients

6 Chapter 6: Local Anesthesia Administration, Dental Materials & Special Care

6.1 Local Anesthesia Pharmacology, Neurophysiology & Vasoconstrictors 6.2 Injection Techniques, Anatomical Landmarks & Nerve Blocks 6.3 Local Anesthesia Complications, Toxicity & Nitrous Oxide Sedation 6.4 Dental Materials Chemistry, Impression Media & Restorative Auxiliaries 6.5 Pit & Fissure Sealants, Polishers & Biomaterial Biocompatibility 6.6 Orthodontic, Endodontic, Pediatric & Implant Patient Care

7 Chapter 7: Infection Prevention, OSHA/CDC Protocols & Medical Emergencies

7.1 Infection Control Principles, Transmission Pathways & Standard Precautions 7.2 Sterilization Methods, Biological Monitoring & Chemical Disinfection 7.3 OSHA Bloodborne Pathogens Standard, HazCom & Regulatory Compliance 7.4 Medical Emergency Recognition, CPR/AED & Protocol Management 7.5 Pharmacological Emergency Interventions & Airway Management 7.6 Instrument Processing Safety, Waste Management & Post-Exposure Protocols

8 Chapter 8: Community Oral Health, Epidemiology & Evidence-Based Research

8.1 Dental Public Health Principles, Community Assessment & Needs Analysis 8.2 Oral Epidemiology Indices: DMF, GI, PI, CPITN, Debris & Calculus Indices 8.3 Community Water Fluoridation Standards, Cost-Benefit & Public Health Policy 8.4 Evidence-Based Decision Making, Research Design, Control Groups & Sampling 8.5 Biostatistics in Dental Research: Mean, Median, P-values, Sensitivity & Specificity

9 Chapter 9: Integrated Case-Based Scenarios, Patient Cases & Professional Ethics

9.1 Case Scenario 1: Complex Periodontal Patient with Systemic Conditions 9.2 Case Scenario 2: Pediatric & Adolescent Preventive Management 9.3 Case Scenario 3: Medically Compromised & Special Needs Geriatric Patient 9.4 Case Scenario 4: Oral Pathology Identification & Interprofessional Referral 9.5 Professional Ethics, Jurisprudence & Dental Hygiene Practice Acts 9.6 Risk Management, Informed Consent & Interprofessional Collaboration

3.2 Analgesics, Opioids, NSAIDs & Central Nervous System Agents

Key Takeaways Explain This Topic AI

NSAIDs inhibit cyclooxygenase (COX-1 and COX-2) enzymes, blocking the conversion of arachidonic acid to pro-inflammatory prostaglandins.

Aspirin causes irreversible covalent inhibition of platelet COX-1, prolonging bleeding time for the 7-10 day lifespan of the platelet, and is contraindicated in children with viral infections due to Reye syndrome.

Acetaminophen (APAP) produces central analgesia and antipyresis without peripheral anti-inflammatory or antiplatelet activity, carrying a strict maximum adult daily limit of 3,000 to 4,000 mg to avoid severe hepatotoxicity.

Opioid analgesics act as agonists at mu-opioid receptors in the central nervous system, inducing analgesia, sedation, respiratory depression, constipation, and characteristic miosis (pinpoint pupils).

Nitrous oxide (N2O) conscious sedation requires a minimum of 30% oxygen delivery and must conclude with 100% pure oxygen administration for 3 to 5 minutes to prevent diffusion hypoxia.

Last updated: July 2026

3.2 Analgesics, Opioids, NSAIDs & Central Nervous System Agents

Core Board Principle: Effective dental pain management requires selecting appropriate analgesic regimens based on inflammatory pathways, pain severity, and patient medical history. Dental hygienists must master the biochemical mechanisms of NSAIDs, acetaminophen, opioids, and CNS depressants, as well as the safe administration protocols for nitrous oxide sedation.

Management of acute and chronic dental pain is a primary clinical responsibility. Understanding the biochemical pathways of inflammation and Central Nervous System (CNS) pharmacology enables the dental hygienist to anticipate drug effects, counsel patients on post-operative analgesia, and ensure safety during conscious sedation.

1. Non-Opioid Analgesics & The Arachidonic Acid Cascade

Tissue trauma caused by dental procedures or periodontal inflammation triggers the breakdown of cell membrane phospholipids by the enzyme Phospholipase A 2 A_2 A 2 ​ , yielding Arachidonic Acid . +---------------------------------------------------------------------------------------+

• | THE ARACHIDONIC ACID PATHWAY |
• +---------------------------------------------------------------------------------------+
• | Cell Membrane Phospholipids ---> Arachidonic Acid (via Phospholipase A2) |
• | | |
• | +-----------------------------+-----------------------------+ |
• | | (Cyclooxygenase Pathway) | (Lipoxygenase) |
• | v v |
• | Cyclooxygenase-1 & 2 (COX-1 / COX-2) 5-Lipoxygenase |
• | | | |
• | +---> Prostaglandins (PGE2: Pain, Inflammation, Fever) +---> Leukotrienes |
• | +---> Thromboxane A2 (TXA2: Platelet Aggregation) (Bronchospasm) |
• | +---> Prostacyclin (PGI2: Vasodilation, Anti-aggregation) |
• +---------------------------------------------------------------------------------------+
• Cyclooxygenase Isoenzymes

COX-1: Constitutively expressed enzyme responsible for physiological baseline functions: maintaining gastric mucosal protection, supporting renal blood flow, and promoting platelet aggregation via Thromboxane A 2 A_2 A 2 ​ .

COX-2: Inducible enzyme synthesized at sites of inflammation in response to cytokines, generating Prostaglandin E 2 E_2 E 2 ​ ( P G E 2 PGE_2 PG E 2 ​ ) , which sensitizes peripheral nociceptors to pain stimuli and induces fever in the hypothalamus.

• 2. NSAIDs, Aspirin & Acetaminophen
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Mechanism: Reversibly inhibit both COX-1 and COX-2 enzymes, decreasing prostaglandin synthesis.

Representative Drugs: Ibuprofen (Advil, Motrin) and Naproxen (Aleve) . Ibuprofen (400–600 mg every 4–6 hours) is the first-line drug of choice for acute inflammatory dental pain.

Adverse Effects: Gastric ulceration/bleeding (due to COX-1 inhibition of protective gastric mucus), reduced renal blood flow, fluid retention, and increased cardiovascular risk (non-aspirin NSAIDs).

Contraindications: Active peptic ulcer disease, severe renal impairment, bleeding disorders, third-trimester pregnancy, and history of NSAID-induced asthma.

Aspirin (Acetylsalicylic Acid - ASA)

Mechanism: Causes irreversible covalent acetylation of COX-1 and COX-2. By irreversibly inhibiting platelet COX-1, aspirin blocks Thromboxane A 2 A_2 A 2 ​ synthesis for the entire lifespan of the platelet ( 7 to 10 days ).

Pharmacological Effects: Analgesic, antipyretic, anti-inflammatory, and antiplatelet.

Aspirin Triad (Samter's Triad): Association of aspirin allergy, nasal polyps, and asthma. Exposure to aspirin in these patients can precipitate severe bronchospasm.

Reye Syndrome: Aspirin is strictly contraindicated in children and adolescents with viral infections (chickenpox or influenza) due to the risk of Reye syndrome—a life-threatening condition characterized by acute encephalopathy and fatty liver failure.

Acetaminophen (APAP / Tylenol)

Mechanism: Acts primarily within the CNS to inhibit prostaglandin synthesis and modulate central pain pathways. It lacks peripheral anti-inflammatory activity and does not inhibit platelet aggregation or cause gastric mucosal ulceration.

Therapeutic Uses: Analgesic and antipyretic of choice for patients with aspirin/NSAID allergies, peptic ulcer disease, bleeding disorders, or pregnancy.

Hepatotoxicity & Dosing Limits: APAP is metabolized by the liver. Excessive doses deplete hepatic glutathione, leading to accumulation of the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) , causing hepatic necrosis.

MAXIMUM DAILY DOSE: The absolute maximum adult daily dose of acetaminophen is 3,000 mg to 4,000 mg (2,000 mg/day in chronic alcoholics or patients with liver disease). The antidote for acetaminophen toxicity is N-acetylcysteine (Mucomyst) .

3. Opioid Analgesics & Antagonists

Opioids manage moderate to severe pain by binding to specific G-protein-coupled receptors in the CNS and peripheral nervous system. +---------------------------------------------------------------------------------+

• | OPIOID RECEPTOR SUBTYPES |
• +----------+----------------------------------------------------------------------+
• | RECEPTOR | PRIMARY PHYSIOLOGICAL RESPONSES |
• +----------+----------------------------------------------------------------------+
• | Mu (μ) | Supraspinal analgesia, respiratory depression, euphoria, sedation, |
• | | physical dependence, constipation, miosis |
• | Kappa (κ)| Spinal analgesia, sedation, miosis, dysphoria/hallucinations |
• | Delta (δ)| Spinal/supraspinal analgesia, modulation of hormone release |
• +----------+----------------------------------------------------------------------+
• Representative Opioid Agonists

Morphine: Standard full μ \mu μ -agonist used as a benchmark for potency.

Codeine: Weak opioid agonist requiring hepatic conversion to morphine via CYP2D6. Frequently combined with acetaminophen (Tylenol #3).

Hydrocodone & Oxycodone: Potent oral opioids combined with acetaminophen (e.g., Vicodin, Percocet) for acute dental pain management.

Fentanyl: Extremely potent synthetic opioid (100 times more potent than morphine) used in conscious sedation and general anesthesia.

Tramadol: Dual-action analgesic: weak μ \mu μ -agonist that also inhibits serotonin and norepinephrine reuptake.

Classic Opioid Adverse Effects & Toxicity Signs

Respiratory Depression: Primary cause of death in opioid overdose due to reduced brainstem sensitivity to carbon dioxide.

Miosis: Characteristic pinpoint pupils (pathognomonic sign of opioid overdose; tolerance does not develop to miosis or constipation).

Constipation & Nausea: Decreased GI motility and direct stimulation of the chemoreceptor trigger zone (CTZ).

Opioid Reversal Agent: Naloxone (Narcan) is a pure competitive opioid receptor antagonist that rapidly reverses opioid-induced respiratory depression.

4. Sedative-Hypnotics, Anxiolytics & General Anesthetics

Central nervous system depressants are widely used in dental practice to manage dental anxiety, provide conscious sedation, and induce general anesthesia.

Benzodiazepines

Mechanism of Action: Bind as positive allosteric modulators to G A B A A GABA_A G A B A A ​ receptors in the CNS, increasing the frequency of inhibitory chloride channel opening. This hyperpolarizes neuronal membranes, producing anxiolytic, sedative, anticonvulsant, muscle relaxant, and anterograde amnestic effects.

Clinical Dental Agents: Triazolam (Halcion) (short-acting, ideal for oral conscious sedation), Diazepam (Valium) , Midazolam (Versed) (short-acting IV agent), and Lorazepam (Ativan) .

Reversal Agent: Flumazenil (Romazicon) is a specific competitive antagonist at G A B A A GABA_A G A B A A ​ benzodiazepine binding sites, used for rapid reversal of benzodiazepine-induced overdose or prolonged sedation.

Barbiturates

Mechanism of Action: Bind to G A B A A GABA_A G A B A A ​ receptors and prolong the duration of chloride channel opening. At higher concentrations, barbiturates directly activate chloride channels independently of GABA.

Clinical Characteristics: Possess a narrow therapeutic index, high addiction potential, and strong hepatic CYP450 enzyme induction. Examples include Phenobarbital (anticonvulsant) and Thiopental (ultra-short-acting IV anesthetic for general anesthesia induction).

General Anesthesia Stages (Guedel's Classification)

Stage I (Analgesia / Conscious Sedation): Patient remains conscious and responsive, with reduced pain perception. Nitrous oxide sedation operates in Stage I.

Stage II (Delirium / Excitement): Patient loses consciousness; exhibits involuntary movements, irregular respiration, and hyper-reactivity. Surgical procedures should not be attempted in Stage II.

Stage III (Surgical Anesthesia): Regular respiration, loss of eyelid reflex, muscle relaxation. Ideal stage for major surgical procedures.

Stage IV (Medullary Paralysis / Overdose): Severe respiratory and vasomotor center paralysis. Life-threatening emergency requiring immediate resuscitation.

5. Nitrous Oxide Conscious Sedation Protocols

Nitrous oxide ( N 2 O \text{N}_2\text{O} N 2 ​ O ) combined with oxygen ( O 2 \text{O}_2 O 2 ​ ) provides rapid, controllable conscious sedation and mild analgesia in dental practice.

Pharmacokinetics & Minimum Alveolar Concentration (MAC)

Low Blood-Gas Partition Coefficient (0.47): Nitrous oxide is poorly soluble in blood, resulting in rapid equilibrium between alveolar air and brain tissue, leading to rapid onset of action (3–5 minutes) and rapid recovery.

MAC Value: Nitrous oxide has a MAC of 104%, making it a weak general anesthetic incapable of producing Stage III anesthesia on its own at atmospheric pressure.

Clinical Administration & Safety Guidelines

Oxygen Concentrations: Administration must ALWAYS maintain a minimum of 30% Oxygen (maximum 70% N 2 O \text{N}_2\text{O} N 2 ​ O ) to prevent hypoxia. Typical clinical maintenance ranges between 30% and 50% N 2 O \text{N}_2\text{O} N 2 ​ O .

Diffusion Hypoxia Prevention: Upon terminating N 2 O \text{N}_2\text{O} N 2 ​ O , the clinician MUST administer 100% pure oxygen for 3 to 5 minutes to prevent diffusion hypoxia, which occurs when N 2 O \text{N}_2\text{O} N 2 ​ O rapidly exits blood into alveoli and dilutes oxygen.

Contraindications: Chronic obstructive pulmonary disease (COPD), upper respiratory tract infections, middle ear infections, bowel obstruction, first trimester of pregnancy, and history of drug abuse.

Loading diagram...